Phase 4 N=149 Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Primary: Blood Albumin — 4.02 g/L — p=<0.0125
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT
Gram-Negative Bacterial Infections
Primary: Probability of Target Attainment for 40% fT>MIC — 100; 100 percentage of time above MIC
Phase 1 N=8 Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
Anaemia
Primary: Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites — 184.9863; 138.6511; 162.9366; 131.2826 Hour into…
Phase 4 N=10 Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
Infectious Peritonitis
Primary: Determine Dalbavancin Plasma Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration — 40573.2; 13532.3 mg*h/L
Phase 4 N=35 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin
Chronic Hepatitis C · Hemodialysis
Primary: 1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs) — 13; 8…
Phase 4 N=377 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001
N/A N=2,946 Empowering Patients on Choices for Renal Replacement Therapy (Aim 2)
Chronic Kidney Disease
Primary: Patient's Quality of Life — 34; 38; 35; 27 % of patients
Phase 3 N=184 A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
Depression · End Stage Renal Disease
Primary: Number of Participants Who Initiated Depression Treatment — 57; 54 Participants — p=0.77
N/A N=102 Shared Decision Making in Dialysis
End Stage Renal Disease · Chronic Kidney Diseases
Primary: Mean Feasibility of Intervention Measure — 16.4; 16.1; 19.0 score on a scale
N/A N=852 An Effectiveness-Implementation Trial of SPIRIT in ESRD
End Stage Renal Disease
Primary: Dyad Congruence on Goals-of-Care Tool — 98; 76; 133; 119 dyads
Phase 3 N=4 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Anaemia
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 0 Participants
Phase 2 N=4 L-Carnitine in Peritoneal Dialysis
End-Stage Renal Disease
Primary: Long Dwell Ultrafiltration — 2167 milliliters
Phase 1 N=4 Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis
Peritoneal Dialysis-associated Peritonitis
Primary: Maximum Total Plasma Concentration (Cmax) — 28.7 mg/L
Phase 3 N=251 Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
N/A N=64 Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05